---
title: "Myomectomy During CS: A Retrospective Cohort Study"
nct_id: NCT03270605
overall_status: COMPLETED
sponsor: Mansoura University
study_type: OBSERVATIONAL
primary_condition: Cesarean Section
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03270605.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03270605"
ct_last_update_post_date: 2020-09-01
last_seen_at: "2026-05-12T07:07:05.619Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Myomectomy During CS: A Retrospective Cohort Study

**Official Title:** Myomectomy During Cesarean Section: A Retrospective Cohort Study

**NCT ID:** [NCT03270605](https://clinicaltrials.gov/study/NCT03270605)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 178
- **Lead Sponsor:** Mansoura University
- **Conditions:** Cesarean Section, Uterine Fibroid
- **Start Date:** 2015-01-01
- **Completion Date:** 2019-12-31
- **CT.gov Last Update:** 2020-09-01

## Brief Summary

To evaluate the value of myomectomy during delivery by cesarean section (CS) in pregnant women with uterine fibroids.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 41 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Women who underwent elective CS with presence of uterine fibroid during the index pregnancy documented antenatal and at surgery

Exclusion Criteria:

* Antepartum hemorrhage
* Blood diseases or bleeding tendencies.
* Medical conditions complicating pregnancy.
* Performed another surgical procedure at CS other than myomectomy.
```

## Arms

- **CS with myomectomy** — Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
- **CS without myomectomy** — Women having uterine myoma with pregnancy and delivered by CS without myomectomy

## Interventions

- **Myomectomy** (PROCEDURE) — Surgical removal of uterine fibroid

## Primary Outcomes

- **Deficit in hemoglobin level** _(time frame: 24 hours)_ — Preoperative hemoglobin minus postoperative hemoglobin level (in gm/dl)

## Secondary Outcomes

- **Operative time** _(time frame: 3 hours)_
- **Postoperative hospital stay period** _(time frame: 7 days)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03270605.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03270605*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*